Supplementary Figure Legend from Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in <i>EGFR</i> Wild-type Cancers

PDF file - 7K</p

Supplementary Figure 2 from Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in <i>EGFR</i> Wild-type Cancers

PDF file - 264K</p

Supplementary Data from Association between Smoking History and Tumor Mutation Burden in Advanced Non–Small Cell Lung Cancer

Supplementary Data</p

Supplementary Table 1 from Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in <i>EGFR</i> Wild-type Cancers

PDF file - 8K</p

Supplementary Data from Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer

Supplementary Data from Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cance

Supplementary Figure 1 from Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in <i>EGFR</i> Wild-type Cancers

PDF file - 10K</p

Supplementary Table S1 from Clinical, Pathologic, and Biologic Features Associated with <i>BRAF</i> Mutations in Non–Small Cell Lung Cancer

Supplementary Table S1 - XLS file 32K, Baseline characteristics of the patients with driver alterations in EGFR, KRAS or ALK</p

Supplementary figure legends from Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer

Legends to the supplementary figures</p

Supplementary Figure 1 from Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer

Pathways targeted by the Dana-Farber Targeted Therapy Collection and clinical development status</p

Supplementary Figure 4 from Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer

Chemical structures of lead compounds</p